Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy:... by Schoenfeld, Jonathan D, MD, Giobbie-Hurder, Anita, MS, Ranasinghe, Srinika, PhD, Kao, Katrina Z, BA, Lako, Ana, PhD, Tsuji, Junko, PhD, Liu, Yang, PhD, Brennick, Ryan C, BS, Gentzler, Ryan D, MD, Lee, Carrie, MD, Hubbard, Joleen, MD, Arnold, Susanne M, Prof, Abbruzzese, James L, Prof, Jabbour, Salma K, Prof, Uboha, Nataliya V, MD, Stephans, Kevin L, MD, Johnson, Jennifer M, MD, Park, Haeseong, MD, Villaruz, Liza C, MD, Sharon, Elad, MD, Streicher, Howard, MD, Ahmed, Mansoor M, PhD, Lyon, Hayley, BA, Cibuskis, Carrie, BS, Lennon, Niall, PhD, Jhaveri, Aashna, MS, Yang, Lin, MS, Altreuter, Jennifer, MD, Gunasti, Lauren, BA, Weirather, Jason L, PhD, Mak, Raymond H, MD, Awad, Mark M, MD, Rodig, Scott J, MD, Chen, Helen X, MD, Wu, Catherine J, Prof, Monjazeb, Arta M, Prof, Hodi, F Stephen, Prof

Get full text

Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology... by Zumsteg, Zachary S, MD, Sheth, Siddharth, DO, Jabbour, Salma K, Prof, Patel, Krishnan R, MD, Kimple, Randall J, MD PhD, Williams, Terence M, Prof, Xu-Welliver, Meng, MD PhD, Torres-Saavedra, Pedro A, PhD, Monjazeb, Arta M, Prof, Mayadev, Jyoti, Prof, Finkelstein, Steven E, MD, Buatti, John M, Prof, Patel, Sandip P, MD, Lin, Steven H, Prof

Get full text